These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 8260367)

  • 1. A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). I: Survival and prognostic factors. Medical Research Council Lung Cancer Working Party.
    Bleehen NM; Girling DJ; Machin D; Stephens RJ
    Br J Cancer; 1993 Dec; 68(6):1150-6. PubMed ID: 8260367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). II: Quality of life. Medical Research Council Lung Cancer Working Party.
    Bleehen NM; Girling DJ; Machin D; Stephens RJ
    Br J Cancer; 1993 Dec; 68(6):1157-66. PubMed ID: 7505104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Report to the Medical Research Council by its Lung Cancer Working Party.
    Br J Cancer; 1989 Apr; 59(4):584-90. PubMed ID: 2540789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. Medical Research Council Lung Cancer Working Party.
    Br J Cancer; 1996 Feb; 73(3):406-13. PubMed ID: 8562352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.
    Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Hatlevoll R; Dahle R; Boye N; Wang M; Vigander T; Vilsvik J; Skovlund E; Hannisdal E; Aamdal S;
    J Clin Oncol; 2002 Dec; 20(24):4665-72. PubMed ID: 12488411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council multicenter randomized LU21 trial.
    Thatcher N; Qian W; Clark PI; Hopwood P; Sambrook RJ; Owens R; Stephens RJ; Girling DJ
    J Clin Oncol; 2005 Nov; 23(33):8371-9. PubMed ID: 16293867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
    Wolf M; Havemann K; Holle R; Gropp C; Drings P; Hans K; Schroeder M; Heim M; Dommes M; Mende S
    J Clin Oncol; 1987 Dec; 5(12):1880-9. PubMed ID: 2824710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
    Miller AA; Herndon JE; Hollis DR; Ellerton J; Langleben A; Richards F; Green MR
    J Clin Oncol; 1995 Aug; 13(8):1871-9. PubMed ID: 7636529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
    Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
    Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin and etoposide alternating ifosfamide, vincristine, epirubicin in small cell lung cancer.
    Unsal M; Erturk D
    Saudi Med J; 2003 Jun; 24(6):628-31. PubMed ID: 12847592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclic-alternating versus response-oriented chemotherapy in small-cell lung cancer: a German multicenter randomized trial of 321 patients.
    Wolf M; Pritsch M; Drings P; Hans K; Schroeder M; Flechtner H; Heim M; Hruska D; Mende S; Becker H
    J Clin Oncol; 1991 Apr; 9(4):614-24. PubMed ID: 1648598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
    Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial.
    Spiro SG; Souhami RL; Geddes DM; Ash CM; Quinn H; Harper PG; Tobias JS; Partridge M; Eraut D
    Br J Cancer; 1989 Apr; 59(4):578-83. PubMed ID: 2540788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of cyclophosphamide, doxorubicin, and vincristine with an alternating regimen of methotrexate, etoposide, and cisplatin/cyclophosphamide, doxorubicin, and vincristine in the treatment of extensive-disease small-cell lung carcinoma: a Mid-Atlantic Oncology Program study.
    Wampler GL; Heim WJ; Ellison NM; Ahlgren JD; Fryer JG
    J Clin Oncol; 1991 Aug; 9(8):1438-45. PubMed ID: 1649265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party.
    Girling DJ
    Lancet; 1996 Aug; 348(9027):563-6. PubMed ID: 8774567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of weekly alternating chemotherapy in extensive-stage small cell lung cancer.
    Kalemkerian GP; Ali MA; Luthra K; Wozniak AJ; Valdivieso M; Kraut MJ
    Cancer Invest; 2001; 19(3):234-8. PubMed ID: 11338879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.
    Souhami RL; Spiro SG; Rudd RM; Ruiz de Elvira MC; James LE; Gower NH; Lamont A; Harper PG
    J Natl Cancer Inst; 1997 Apr; 89(8):577-80. PubMed ID: 9106647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination chemotherapy of limited-stage small-cell lung cancer. A controlled trial on 221 patients comparing two alternating regimens.
    Osterlind K; Hansen M; Hirsch FR; Dombernowsky P; Sörenson S; Pedersen AG; Hansen HH
    Ann Oncol; 1991 Jan; 2(1):41-6. PubMed ID: 1848996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of hyperfractionated radiotherapy and concurrent weekly alternating chemotherapy in limited-stage small cell lung cancer.
    Ali MA; Kraut MJ; Valdivieso M; Herskovic AM; Du W; Kalemkerian GP
    Lung Cancer; 1998 Oct; 22(1):39-44. PubMed ID: 9869106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised trial of low-dose/high-frequency chemotherapy as palliative treatment of poor-prognosis small-cell lung cancer: a Cancer research Campaign trial.
    James LE; Gower NH; Rudd RM; Spiro SG; Harper PG; Trask CW; Partridge M; Ruiz de Elvira MC; Souhami RL
    Br J Cancer; 1996 Jun; 73(12):1563-8. PubMed ID: 8664131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.